AbbVie Inc. (ABBV) on Monday said it has submitted an application to the U.S. Food and Drug Administration seeking approval for a subcutaneous induction regimen of SKYRIZI for adults with moderately to severely active Crohn's disease.
The filing is backed by positive Phase 3 AFFIRM study results, which evaluated the efficacy and safety of subcutaneous SKYRIZI as an induction treatment, including in patients with prior advanced therapy failure.
SKYRIZI was first approved in 2022 for Crohn's disease, and AbbVie expects a decision on the new dosing regimen later this year.
AbbVie shares closed at $198.71 on Friday, down 1.11%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.